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Aberrant expression of cyclin-dependent kinase (CDK) inhibitors is implicated in the car-
cinogenesis of many cancers, including ovarian and endometrial cancers. We examined
associations between CDK inhibitor expression, cancer risk factors, tumor characteris-
tics, and survival outcomes among ovarian and endometrial cancer patients enrolled in
a population-based case-control study. Expression (negative vs. positive) of three CDK
inhibitors (p16, p21, and p27) and ki67 was examined with immunohistochemical stain-
ing of tissue microarrays. Logistic regression was used to estimate adjusted odds ratios
(ORs) and 95% confidence intervals (CIs) for associations between biomarkers, risk fac-
tors, and tumor characteristics. Survival outcomes were only available for ovarian cancer
patients and examined using Kaplan–Meier plots and Cox proportional hazards regression.
Among ovarian cancer patients (n=175), positive p21 expression was associated with
endometrioid tumors (OR=12.22, 95% CI=1.45–102.78) and higher overall survival (log-
rank p=0.002). In Cox models adjusted for stage, grade, and histology, the association
between p21 expression and overall survival was borderline significant (hazard ratio=0.65,
95% CI=0.42–1.05). Among endometrial cancer patients (n=289), positive p21 expres-
sion was inversely associated with age (OR≥65 years of age=0.25, 95% CI=0.07–0.84)
and current smoking status (OR: 0.33, 95% CI 0.15, 0.72) compared to negative expres-
sion. Our study showed heterogeneity in expression of cell-cycle proteins associated with
risk factors and tumor characteristics of gynecologic cancers. Future studies to assess
these markers of etiological classification and behavior may be warranted.
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INTRODUCTION
Dysregulation of cell-cycle control mechanisms has been observed
in many human cancers (1). Cell-cycle checkpoints control the
timing of transitions to ensure appropriate DNA replication. Pas-
sage through the G1 checkpoint is influenced by the retinoblas-
toma protein (pRb), which in turn is regulated by the activity of
cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors.
The CDK inhibitors, p16, p21, and p27, interact with cyclin-CDK
complexes to down-regulate phosphorylation of pRb, inhibiting
G1 progression, and restricting cell growth. Alterations resulting in
overexpression of cell-cycle stimulating proteins (cyclins or CDKs)
or inactivation of inhibiting factors (CDK inhibitors or pRb) have
the potential to disrupt the cell-cycle and initiate uncontrolled cell
proliferation (2).
Aberrant expression of the CDK inhibitors has been frequently
characterized among women with ovarian and endometrial can-
cers (3); however, relationships between these biomarkers with
tumor characteristics and survival have offered a conflicting por-
trait. For example, among ovarian cancer patients, positive p16
expression has been associated with less favorable tumor char-
acteristics by some (4–8) but not others (9–12). Furthermore,
the prognostic significance of p16 is highly variable in ovarian
cancer studies, with some reporting lower mortality (4, 5, 11),
higher mortality (6, 8), or no association (7, 10, 12). Loss of
p21 and p27 expressions is typically associated with worse grade,
stage, and survival among ovarian cancer patients (13–17). Several
studies have reported similarly inconsistent relationships between
cell-cycle markers and tumor characteristics among women with
endometrial cancer (18–27).
To our knowledge, no previous study has investigated associa-
tions between the CDK inhibitors and etiologic risk factors associ-
ated with development of these two cancers. Molecular epidemi-
ologic studies can advance our understanding of the pathogenesis
of gynecologic malignancies. Therefore, we examined associations
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between cell-cycle proteins, epidemiologic risk factors, tumor
characteristics, and survival among ovarian and endometrial can-
cer patients to examine etiologic heterogeneity at the molecular
level. We hypothesize that aberrant cell-cycle protein expression
would be associated with risk factors for these two malignancies
as well as unfavorable tumor characteristics and poor survival.
MATERIALS AND METHODS
STUDY POPULATION
Data for this study are available from the population-based case-
control Polish Cancer Study, which has been described previ-
ously (28, 29). Briefly, eligible cases were diagnosed between June
1, 2001 and December 30, 2003, resided in Warsaw or Lodz,
Poland, and aged 20–74 at the time of diagnosis. For the cur-
rent study, incident ovarian (N = 317) and endometrial (N = 551)
cancer cases were ascertained through a rapid identification system
coordinated by five participating Polish hospitals, which cov-
ers approximately 85% of all cases diagnosed in the two cities
(28). Additionally, cancer registries in Warsaw and Lodz were
used to identify cases missed by the rapid identification system.
Interviewer administered questionnaires collected information on
demographics, anthropometric factors, reproductive character-
istics, exogenous hormone use, and cigarette smoking. Medical
records were reviewed for pathology, treatment, and outcomes
information. One pathologist (MES) verified the pathologic diag-
nosis through hematoxylin and eosin (H&E) slide review. This
study was reviewed and approved by the institutional review
boards (IRBS) of the U.S. National Cancer Institute (NCI), the
M. Sklodowska Curie Institute of Oncology and Cancer Center in
Warsaw, and the Institute of Occupational Medicine in Lodz. This
study is covered by Single Project Assurances (SPAs) in Warsaw
(S-009741-04) and Lodz (S-017191-01). All participants provided
written informed consent for use of clinical data and archival tissue
specimens.
PATHOLOGY
Formalin-fixed paraffin-embedded tissue blocks were available for
a subset of ovarian (55%) and endometrial (52%) cancer cases.
Tissue microarrays (TMAs) were constructed at Yale University
after H&E stained slides were retrieved to mark representative
areas of each tumor. Between two and four cores, 0.6-mm in diam-
eter were punched from donor blocks and transferred to recipient
blocks. Sections were cut from each TMA block and immunohis-
tochemical stains for p21, p27, and a dual stain for p16 and ki67
were performed at the Applied Molecular Pathology Laboratory at
the NCI.
IMMUNOHISTOCHEMICAL STAINING AND SCORING
All TMA formalin-fixed paraffin-embedded sections were
deparaffinized through xylene and rehydrated in graded ethanols.
Antigen retrieval was carried out in a pressure cooker using DAKO
citrate buffer, pH6.0 for p27, and DAKO Tris/EDTA, pH9.0 for
monoclonal mouse p21 for 20 min. Endogenous peroxidase activ-
ity was quenched with 3% H202 for 10 min followed by primary
antibody application of rabbit polyclonal anti-p27 (Thermo Sci-
entific, Pittsburgh, PA, USA, clone Kip1) at 1:1000 for 30 min and
mouse monoclonal anti-p21 (DAKO, Carpinteria, CA, USA, Clone
SX118) at 1:25 for 2 h. Antigen–antibody complexes were detected
with DAKO Env+ detection system and 3,3-diaminobenzidine,
counterstained with hematoxylin, dehydrated, and coverslipped.
For antibody p16/ki67, the immunohistochemical assay was per-
formed using CINtec PLUS Kit (Westborough, MA, USA, cata-
log 9537) using their recommended procedures for simultaneous
qualitative detection of p16 (INK4a) and Ki67 antigens mod-
ified slightly and respectively for histologic specimens. Slides
were imaged on a Hamamatsu Nanozoomer and one patholo-
gist (MES) evaluated and scored the ovarian TMA slides while
two cytotechnologists evaluated the endometrial TMA slides (RLC
and VB) using the SlidePath Digital Image Hub (Leica Microsys-
tems, Dublin, Ireland). For the endometrial TMA, there was no
overlap in the stains read by the two cytotechnologists – e.g., one
cytotechnologist read all of the p16/ki67 stains while the second
cytotechnologist read all of the p21 and p27 stains.
The percentage of stained cells (range: 0–100%) and intensity
(0= negative, 1=weak, 2=moderate, 3= strong) were recorded
for each marker. An overall score was calculated as the prod-
uct of the percentage of stained cells and intensity, resulting in
a range of 0 and 300 for each core. All p16/ki67 double stains
showed strong intensity; therefore, only the percentage of stained
cells was used for these markers (range: 0–100%). Protein expres-
sion was dichotomized as negative (<10) vs. positive (≥10) for
all markers and representative immunohistochemical stains are
shown in Figure S1 in Supplementary Material. Established IHC
cut points for these markers do not exist; therefore, we chose the
threshold of 10 based on the observed distribution of the over-
all scores in our study population and our biological hypothesis
that loss of expression of the CDK inhibitors is clinically rele-
vant. Sensitivity analyses using other cut points to denote negative
and positive expression (0 vs. ≥0, 0–19 vs. ≥20) did not pro-
duce differences in associations. For each stain, we examined the
correlation between multiple TMA cores using Spearman’s rank
correlation statistic, which was>0.82 among ovarian cancer cases
and >0.69 among endometrial cancer cases. Average and high-
est values of the cores were similar and the highest value of the
cores was used in all analyses. Sensitivity analyses using the aver-
age of the cores were run and the results did not appreciably
change.
STATISTICAL ANALYSIS
Correlations between markers were assessed with Spearman’s rank
correlation statistic using the overall score for p21 and p27 and
the percentage of stained cells for p16 and ki67 by cancer site
overall and by histologic subtype among ovarian cancer patients.
Relationships between p16, p21, and p27 expression, epidemio-
logic risk factors, and tumor characteristics were first assessed
using Pearson chi-square tests. Logistic regression was used to
generate multivariable adjusted odds ratios (ORs) and 95% confi-
dence intervals (CIs) predicting positive vs. negative expression of
each marker. The relationship between marker expression and epi-
demiologic characteristics was adjusted for age,menopausal status,
menopausal hormone use, smoking status, body mass index, par-
ity, and oral contraceptive use. The relationship between marker
expression and tumor characteristics was adjusted for age, grade,
stage, and histology. Information on epidemiologic risk factors was
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Table 1 | Selected characteristics of ovarian and endometrial cancer cases in the Polish Cancer Study by inclusion on the tissue microarray
(TMA).
Ovarian cancer Endometrial cancer
Not included onTMA Included onTMA p Not included onTMA Included onTMA pa
n=142 n=175 n=262 n=289
n (%) n (%) n (%) n (%)
Age 0.47 0.22
<50 39 (27.5) 58 (33.1) 34 (13.0) 24 (8.3)
50–54 26 (18.3) 22 (12.6) 36 (13.7) 39 (13.5)
55–64 34 (23.9) 42 (24.0) 100 (38.2) 106 (36.7)
65+ 43 (30.3) 53 (30.3) 95 (35.1) 120 (41.5)
Menopausal status 0.31 0.29
Premenopausal 33 (23.2) 50 (28.6) 43 (16.4) 36 (12.5)
Postmenopausal 93 (65.5) 100 (57.1) 196 (74.8) 220 (76.1)
Missing 16 (11.3) 25 (14.3) 23 (8.8) 33 (11.4)
Menopausal hormone use 0.83 0.37
No 106 (74.6) 134 (76.7) 194 (74.0) 210 (72.7)
Yes 36 (25.3) 40 (22.9) 63 (24.0) 77 (26.6)
Missing 0 (0.0) 1 (0.6) 5 (1.9) 2 (0.7)
Smoking status 0.51 0.03
Non-smoker 68 (47.9) 73 (41.7) 158 (60.3) 200 (69.2)
Past 27 (19.0) 40 (22.9) 45 (17.2) 48 (16.6)
Current 47 (33.1) 62 (35.4) 59 (22.5) 41 (14.2)
Body mass index 0.32 0.86
<25 90 (63.4) 96 (54.9) 77 (29.4) 81 (28.0)
25–30 34 (23.9) 50 (28.6) 93 (35.5) 113 (39.1)
>30 16 (11.3) 28 (16.0) 89 (34.0) 92 (31.8)
Missing 2 (1.4) 1 (0.6) 3 (1.1) 3 (1.0)
Parity 0.91 0.03
Nulliparous 30 (21.1) 35 (20.0) 41 (15.6) 61 (21.1)
1–2 Live births 103 (72.5) 127 (72.6) 188 (71.8) 208 (72.0)
≥3 Live births 9 (6.3) 13 (7.4) 33 (12.6) 20 (6.9)
Oral contraceptive use 0.74 0.10
No 128 (90.1) 162 (92.6) 243 (92.7) 277 (95.8)
Yes 12 (8.4) 11 (6.3) 16 (6.1) 12 (4.1)
Missing 2 (1.4) 2 (1.1) 3 (1.1) 0 (0.0)
Grade <0.0001 <0.0001
I 9 (6.3) 37 (21.1) 95 (36.3) 206 (71.3)
≥II 44 (31.0) 129 (73.7) 37 (14.1) 80 (27.7)
Missing 89 (62.7) 9 (5.1) 130 (49.6) 3 (1.0)
Stage <0.0001 <0.0001
I 23 (16.2) 64 (36.6) 105 (40.1) 208 (72.0)
≥II 36 (25.3) 92 (52.6) 29 (11.1) 45 (15.6)
Missing 83 (58.4) 19 (10.9) 128 (48.8) 36 (12.5)
Histology 0.003 <0.0001
Serous 60 (42.2) 74 (42.3) 9 (3.4) 1 (0.3)
Endometrioid 29 (20.4) 19 (10.9) 208 (79.4) 223 (77.2)
Mucinous 10 (7.0) 10 (5.7) 3 (1.1) 1 (0.3)
Mixed epithelial 11 (7.7) 40 (22.9) 19 (7.2) 50 (17.3)
Clear cell 4 (2.8) 7 (4.0) 4 (1.5) 1 (0.3)
Carcinosarcoma – – 5 (1.9) 10 (3.5)
Other 28 (19.7) 25 (14.3) 14 (5.3) 3 (1.0)
aFisher’s exact p-value reported when >25% of cell counts are <5.
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available as previously described (28). Grade and stage were avail-
able for ovarian and endometrial cancer cases. Because of small
numbers, we examined grade I vs. grades II or higher, and stage I vs.
stages II or higher. Ovarian histology included serous, endometri-
oid, clear cell, mucinous, and mixed epithelial. The predominant
histology of endometrial cancers was endometrioid.
For ovarian cancer patients, we had additional information on
survival from medical records. We did not examine relationships
between biomarker expression and endometrial cancer outcomes
given the small number of deaths. Overall survival was defined as
the number of days between the date of surgery and the date of
death from all causes or the date of last follow-up. Kaplan–Meier
curves compared overall survival according to marker expression.
When a marker was significantly associated with overall survival,
we used Cox proportional hazards regression to estimate hazard
ratios (HRs) and 95% CIs adjusted for stage, histology, and grade.
We generated a heat map to compare distributions of p16, p21,
p27, and ki67 expression across ovarian cancer histology types and
endometrioid endometrial cancer. All markers were transformed
to the same scale (0–300) and the continuous value of each marker
for each individual case was grouped according to histology type.
The Kurman and Shih paradigm of epithelial ovarian carcinoma
pathogenesis guided the categorization of ovarian cancers (30). All
statistical analyses were performed using the SAS Software Pack-
age, version 9.3 (SAS Institute, Cary, NC, USA) and a two-sided
p≤ 0.05 was considered statistically significant.
RESULTS
STUDY POPULATION
Table 1 shows distributions of epidemiologic and tumor char-
acteristics among ovarian and endometrial cancer patients by
TMA inclusion status. Tumor characteristics significantly differed
between those included and not included on the TMA; for the most
part, cases with missing grade, stage, or other histology were less
likely to be included on either the ovarian or endometrial TMA.
Non-smokers were more likely to be included on the endometrial
TMA.
CORRELATIONS BETWEEN CELL-CYCLE MARKERS
Spearman correlations between the continuous values of all cell-
cycle markers by cancer site are shown in Table 2. Among ovarian
cancer patients, significant positive correlations were observed for
p27 with p16 (p< 0.0001) and ki67 (p< 0.0001), but a significant
inverse association between p27 and p21 was observed. Among
endometrial cancer patients, we noted significant positive correla-
tions between p27 and p16 (p< 0.05), p27 and p21 (p< 0.0001),
and p27 and ki67 (p< 0.0001).
CELL-CYCLE EXPRESSION AMONG OVARIAN CANCER PATIENTS
Table 3 shows associations between dichotomous cell-cycle and
ki67 expression, epidemiologic risk factors, and tumor character-
istics among ovarian cancer cases. Positive expression of p16, p21,
p27, and ki67 was observed in 79, 68, 80, and 64% of ovarian can-
cer patients, respectively. None of the epidemiological risk factors
were significantly associated with expressions of the four markers.
Compared to negative expression, positive p16 (OR= 3.15, 95%
CI= 1.09–9.07) and positive ki67 (OR= 4.61, 95% CI= 1.70–
12.58) were associated with higher odds of grades II and III tumors
Table 2 | Spearman correlation coefficients between cell-cycle markers
by cancer site.
p16 p21 p27 ki67
Ovarian cancer, n=175
p16 – −0.11 0.33** 0.09
p21 – – −0.45** −0.10
p27 – – – 0.44**
ki67 – – – –
Serous ovarian, n=73
p16 – −0.05 0.11 0.03
p21 – – −0.13 −0.06
p27 – – – 0.35*
ki67 – – – –
Non-serous ovarian, n=75 a
p16 – 0.09 0.35* 0.03
p21 – – −0.25* 0.004
p27 – – – 0.44**
ki67 – – – –
Endometrial cancer, n=289 b
p16 – 0.11 0.17* 0.17*
p21 – – 0.37** 0.41**
p27 – – – 0.38**
ki67 – – – –
aNon-serous ovarian cancers include mixed epithelial (n= 39), endometrioid
(n=19), mucinous (n=10), and clear cell (n=7).
bEndometrial tumors were predominantly endometrioid.
*p<0.05.
**p<0.0001.
while positive p21 was associated with higher odds of endometri-
oid tumors (OR= 12.22, 95% CI= 1.45–102.78). Compared to
negative p27 expression, positive p27 expression was inversely
associated with most of the ovarian cancer histologic subtypes,
including endometrioid, mucinous, and clear cell tumors.
Median follow-up time was 4.41 years among ovarian cancer
patients (range: 0.19–10.43 years) and 56% (n= 98) of ovarian
cancer patients died. Kaplan–Meier graphs of the cell-cycle mark-
ers and overall survival are shown in Figure 1. Positive p21 expres-
sion was associated with better survival compared with negative
p21 expression (log-rank p= 0.002). Adjustment for stage, histol-
ogy, and grade attenuated the association between p21 expression
and overall survival (HR= 0.66, 95% CI= 0.42–1.05). We also
explored relationships between cell-cycle expression and survival
among the ovarian cancer histologic subtypes. Positive p21 expres-
sion was associated with better survival among the women with
endometrioid (HR= 0.02, 95% CI= 0.00–0.55) but not serous
(HR= 0.97, 95% CI= 0.54–1.73) tumors in models adjusted for
stage and grade. No association between p16, p27, ki67, and overall
survival were observed in the overall study population (Figure 1)
or in subgroups defined by stage (data not shown).
CELL-CYCLE EXPRESSION AMONG ENDOMETRIAL CANCER PATIENTS
Associations for endometrial cancer patients are described in
Table 4. Positive expression of p16,p21,p27,and ki67 was observed
in 89, 46, 80, and 81% of cases, respectively. Positive p21 expression
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Table 3 | Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of risk factors and tumor characteristics for positive vs. negative expression of cell-cycle markers among ovarian
cancer patients (n=175).
p16 p21 p27 ki67
Negative
(n=35)
Positive
(n=138)
OR (95% CI)a Negative
(n=56)
Positive
(n=118)
OR (95% CI)a Negative
(n=35)
Positive
(n=139)
OR (95% CI)a Negative
(n=62)
Positive
(n=111)
OR (95% CI)a
n (%) n (%) n (%) n (%)
Age
<50 6 (17.1) 52 (37.7) 1.00 14 (25.0) 44 (37.3) 1.00 8 (22.9) 50 (36.0) 1.00 20 (32.3) 38 (34.2) 1.00
50–54 7(20.0) 15 (10.9) 0.20 (0.04, 0.92) 5 (8.9) 17 (14.4) 2.91 (0.63, 13.47) 6 (17.1) 16 (11.5) 0.31 (0.07, 1.44) 8 (12.9) 14 (12.6) 0.69 (0.19, 2.42)
55–64 8 (22.9) 33 (23.9) 0.45 (0.09, 2.24) 16 (28.6) 25 (21.2) 1.14 (0.29, 4.37) 5 (14.3) 36 (25.9) 1.06 (0.18, 6.14) 9 (14.5) 32 (28.8) 1.43 (0.37, 5.51)
65+ 14 (40.0) 38 (27.5) 0.25 (0.05, 1.29) 21 (37.5) 32 (27.1) 1.01 (0.25, 4.01) 16 (45.7) 37 (26.6) 0.36 (0.07, 1.90) 25 (40.3) 27 (24.3) 0.36 (0.09, 1.38)
pb 0.15 0.47 0.13 0.06
Menopausal status
Premenopausal 6 (17.1) 44 (31.9) 1.00 7 (12.5) 43 (36.4) 1.00 8 (22.9) 42 (30.2) 1.00 19 (30.6) 31 (27.9) 1.00
Postmenopausal 22 (62.9) 76 (55.1) 1.00 (0.21, 4.77) 36 (64.3) 63 (53.4) 0.28 (0.07, 1.18) 23 (65.7) 76 (54.7) 1.07 (0.22, 5.29) 35 (56.4) 63 (56.8) 2.19 (0.61, 7.77)
pb 0.47 0.68 0.96 0.41
Menopausal hormone use
No 27 (77.1) 106 (76.8) 1.00 42 (75.0) 92 (78.0) 1.00 31 (88.6) 103 (74.1) 1.00 49 (79.0) 84 (75.7) 1.00
Yes 8 (22.9) 31 (22.5) 0.68 (0.25, 1.83) 13 (23.2) 26 (22.0) 0.84 (0.35, 1.99) 4 (11.4) 35 (25.2) 2.18 (0.68, 6.98) 13 (21.0) 25 (22.5) 0.84 (0.37, 1.92)
pb 0.44 0.69 0.19 0.68
Smoking status
Non-smoker 14 (40.0) 59 (42.7) 1.00 24 (42.9) 49 (41.5) 1.00 14 (40.0) 59 (42.4) 1.00 29 (46.8) 44 (39.6) 1.00
Former 7 (20.0) 31 (22.5) 1.25 (0.39, 4.01) 12 (21.4) 27 (22.9) 1.09 (0.43, 2.80) 8 (22.9) 31 (22.3) 0.86 (0.29, 2.50) 13 (21.0) 25 (22.5) 1.10 (0.44, 2.73)
Current 14 (40.0) 48 (34.8) 0.70 (0.26, 1.91) 20 (35.7) 42 (35.6) 0.82 (0.35, 1.92) 13 (37.1) 49 (35.2) 0.92 (0.34, 2.46) 20 (32.3) 42 (37.8) 1.19 (0.52, 2.69)
pb 0.59 0.83 0.96 0.92
Body mass index
<25 20 (57.1) 76 (55.1) 1.00 30 (53.6) 66 (55.9) 1.00 20 (57.1) 76 (54.7) 1.00 33 (53.2) 63 (56.8) 1.00
25–30 13 (37.1) 36 (26.1) 0.75 (0.29, 1.90) 14 (25.0) 36 (30.5) 1.35 (0.57, 3.17) 12 (34.3) 38 (27.3) 1.02 (0.41, 2.53) 18 (29.0) 31 (27.9) 0.96 (0.42, 2.18)
>30 2 (5.7) 25 (18.1) 4.69 (0.90, 24.39) 11 (19.6) 16 (13.6) 0.85 (0.31, 2.35) 3 (8.6) 24 (17.3) 2.90 (0.73, 11.57) 11 (17.7) 16 (14.4) 0.68 (0.25, 1.84)
pb 0.10 0.67 0.30 0.74
Parity
Nulliparous 10 (28.6) 24 (17.4) 1.00 9 (16.1) 25 (21.2) 1.00 5 (14.3) 29 (20.9) 1.00 12 (19.3) 22 (19.8) 1.00
1–2 Live births 22 (62.9) 104 (75.4) 2.31 (0.88, 6.02) 42 (75.0) 85 (72.0) 0.66 (0.26, 1.70) 27 (77.1) 100 (71.9) 0.58 (0.19, 1.74) 42 (67.7) 84 (75.7) 1.02 (0.44, 2.37)
≥3 Live births 3 (8.6) 10 (7.2) 1.50 (0.28, 8.14) 5 (8.9) 8 (6.8) 0.64 (0.13, 3.14) 3 (8.6) 10 (7.2) 0.56 (0.10, 3.32) 8 (12.9) 5 (4.5) 0.33 (0.07, 1.51)
pb 0.22 0.69 0.61 0.27
Oral contraceptive use
Never 34 (97.1) 126 (91.3) 1.00 52 (92.9) 109 (92.4) 1.00 34 (97.1) 127 (91.4) 1.00 59 (95.2) 101 (91.0) 1.00
Ever 1 (2.9) 10 (7.2) 3.30 (0.35, 31.12) 2 (3.6) 9 (7.6) 2.57 (0.45, 14.72) 1 (2.9) 10 (7.2) 2.05 (0.23, 18.56) 2 (3.2) 9 (8.1) 2.93 (0.56, 15.32)
pb 0.30 0.29 0.52 0.20
(Continued)
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Table 3 | Continued
p16 p21 p27 ki67
Negative
(n=35)
Positive
(n=138)
OR (95% CI)c Negative
(n=56)
Positive
(n=118)
OR (95% CI)c Negative
(n=35)
Positive
(n=139)
OR (95% CI)c Negative
(n=62)
Positive
(n=111)
OR (95% CI)c
n (%) n (%) n (%) n (%)
Grade
I 15 (42.9) 21 (15.2) 1.00 6 (10.7) 31 (26.3) 1.00 12 (34.3) 25 (18.0) 1.00 21 (33.9) 15 (13.5) 1.00
≥II 19 (54.3) 109 (79.0) 3.15 (1.09, 9.07) 50 (89.3) 78 (66.1) 0.53 (0.17, 1.67) 19 (54.3) 109 (78.4) 1.17 (0.39, 3.56) 34 (54.8) 94 (84.7) 4.61 (1.70, 12.58)
pb 0.05 0.56 0.75 0.004
Stage
I 16 (45.7) 48 (34.8) 1.00 11 (19.6) 53 (44.9) 1.00 20 (57.1) 44 (31.6) 1.00 30 (48.4) 34 (30.6) 1.00
≥II 15 (42.9) 75 (54.3) 0.95 (0.36, 2.54) 36 (64.3) 55 (46.6) 0.57 (0.24, 1.39) 11 (31.4) 80 (57.5) 2.15 (0.80, 5.75) 25 (40.3) 65 (58.6) 1.52 (0.67, 3.47)
pb 0.42 0.31 0.16 0.54
Histology
Serous 10 (28.6) 63 (45.6) 1.00 36 (64.3) 37 (31.4) 1.00 5 (14.3) 68 (48.9) 1.00 21 (33.9) 52 (46.8) 1.00
Endometrioid 6 (17.1) 13 (9.4) 0.56 (0.14, 2.22) 1 (1.8) 18 (15.2) 12.22 (1.45, 102.78) 7 (20.0) 12 (8.6) 0.13 (0.03, 0.60) 6 (9.7) 13 (11.7) 2.16 (0.56, 8.40)
Mucinous 5 (14.3) 5 (3.6) 0.16 (0.03, 0.96) 1 (1.8) 9 (7.6) 3.34 (0.33, 33.52) 4 (11.4) 6 (4.3) 0.13 (0.02, 0.81) 5 (8.1) 5 (4.5) 1.45 (0.29, 7.21)
Mixed epithelial 5 (14.3) 34 (24.6) 1.33 (0.38, 4.62) 13 (23.2) 27 (22.9) 1.90 (0.80, 4.48) 7 (20.0) 33 (23.7) 0.38 (0.10, 1.41) 12 (19.3) 27 (24.3) 1.09 (0.43, 2.80)
Clear cell 2 (5.7) 5 (3.6) 0.30 (0.04, 2.18) 1 (1.8) 6 (5.1) 5.91 (0.58, 60.27) 3 (8.6) 4 (2.9) 0.13 (0.02, 0.84) 4 (6.4) 3 (2.7) 0.39 (0.07, 2.16)
Other 7 (20.0) 18 (13.0) 0.38 (0.11, 1.32) 4 (7.1) 21 (17.8) 3.90 (1.13, 13.49) 9 (25.7) 16 (11.5) 0.17 (0.04, 0.64) 14 (22.6) 11 (9.9) 0.48 (0.17, 1.37)
pb 0.16 0.05 0.05 0.38
aLogistic regressionmodel predicting positive vs. negative expression of themarker adjusted for age,menopausal status,menopausal hormone use, smoking status, bodymass index, parity, and oral contraceptive use.
bChi-square p from logistic regression model.
cLogistic regression model predicting positive vs. negative expression of the marker adjusted for age, grade, stage, and histology.
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FIGURE 1 | Kaplan–Meier overall survival curves by p16, p21, p27, and ki67 expression among ovarian cancer patients.
decreased with older age (OR for ≥65 years: 0.28, 95% CI 0.08,
0.93) and current smoking (OR: 0.30, 95% CI 0.13, 0.68). Posi-
tive ki67 expression also decreased with older age at endometrial
cancer diagnosis (OR for diagnosis 50–54 years: 0.13, 95% CI 0.02,
0.69). No significant associations between the cell-cycle or ki67
markers and endometrial tumor characteristics were observed
(p> 0.15).
DISTRIBUTION OF CELL-CYCLE EXPRESSIONS IN HISTOLOGIC
SUBTYPES
The distribution of cell-cycle and ki67 expression in histologic sub-
types of ovarian cancer (low and high-grade serous, mixed epithe-
lial, mucinous, endometrioid, and clear cell) and in endometri-
oid endometrial cancer patients is shown in Figure 2. Cells
of light yellow indicate negative or low expression while dark
orange cells indicate positive or high expression of the bio-
marker. Women with non-serous ovarian histology (mucinous,
endometrioid, and clear cell tumors) had similar cell-cycle pro-
tein expression patterns: expression of p16, p27, and ki67 were
negative while p21 expression was positive among these three sub-
groups. Serous ovarian cancers had a unique expression pattern
dependent on grade: high-grade serous tumors were character-
ized by negative p21 expression while some low-grade serous
tumors showed positive p21 expression. The mixed epithelial
tumors had expression patterns intermediate to the serous and
other non-serous subtypes, with positive p16 expression and
negative expression of the other markers. Cell-cycle expression
patterns among the endometrioid endometrial cancers showed
intermediate expression of p16 and relatively low expression of
the other markers.
DISCUSSION
In this population-based study, we examined relationships
between CDK inhibitors, epidemiologic risk factors, and tumor
characteristics among ovarian and endometrial cancer patients.
To our knowledge, this is the first study exploring relation-
ships between these biomarkers and etiologic factors related to
these gynecologic malignancies. The recently completed Cancer
Genome Atlas (TCGA) studies of ovarian and endometrial cancers
(31, 32) have provided ample evidence for molecular heterogeneity
within histologic subtypes of these malignancies (31, 32); there-
fore, assessing relationships between molecular biomarkers and
epidemiologic factors may reveal etiologic pathways beyond that
of risk factor associations with histologic subtypes.
A large body of literature supports the notion that dysregulation
of cell-cycle control, particularly the transition from G1 to S phase,
is an important prerequisite for development of many epithelial
malignancies (33). This transition requires phosphorylation of the
pRb, which in turn is controlled by the activity of several classes
of proteins, including cyclins, CDKs, and CDK inhibitors. This
latter group of proteins, which include p16, p21, and p27, acts as
negative regulators of the cell-cycle by preventing phosphoryla-
tion of pRb and arresting progression of the cell-cycle. The TCGA
analysis of high-grade serous ovarian cancers reported that the Rb
pathway was deregulated in 67% of cases (31). Moreover, a recently
engineered mouse model recapitulating initiation and progression
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Table 4 | Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of risk factors and tumor characteristics for positive vs. negative expression of cell-cycle markers among
endometrial cancer patients (n=289).
p16 p21 p27 ki67
Negative
(n=30)
Positive
(n=255)
OR (95% CI)a Negative
(n=154)
Positive
(n=132)
OR (95% CI)a Negative
(n=58)
Positive
(n=228)
OR (95% CI)a Negative
(n=55)
Positive
(n=230)
OR (95% CI)a
n (%) n (%) n (%) n (%)
Age
<50 2 (6.7) 22 (8.6) 1.00 9 (5.8) 15 (11.4) 1.00 4 (6.9) 20 (8.8) 1.00 2 (3.6) 22 (9.6) 1.00
50–54 8 (26.7) 30 (11.8) 0.43 (0.07, 2.71) 23 (14.9) 16 (12.1) 0.35 (0.11, 1.12) 13 (22.4) 26 (11.4) 0.60 (0.15, 2.37) 15 (27.3) 23 (10.0) 0.13 (0.02, 0.69)
55–64 10 (33.3) 94 (36.9) 1.16 (0.16, 8.42) 50 (32.5) 54 (40.9) 0.49 (0.15, 1.59) 20 (34.5) 84 (36.8) 1.43 (0.34, 6.02) 16 (29.1) 88 (38.3) 0.53 (0.09, 3.12)
65+ 10 (33.3) 109 (42.8) 1.37 (0.18, 10.67) 72 (46.8) 47 (35.6) 0.28 (0.08, 0.93) 21 (36.2) 98 (43.0) 1.76 (0.40, 7.73) 22 (40.0) 97 (42.2) 0.47 (0.08, 2.85)
pb 0.31 0.07 0.21 0.01
Menopausal status
Premenopausal 5 (16.7) 31 (12.2) 1.00 18 (11.7) 18 (13.6) 1.00 7 (12.1) 29 (12.7) 1.00 8 (14.5) 28 (12.2) 1.00
Postmenopausal 23 (76.7) 194 (76.1) 0.76 (0.18, 3.14) 119 (77.3) 98 (74.2) 1.23 (0.44, 3.73) 45 (77.6) 172 (75.4) 0.55 (0.17, 1.78) 42 (76.4) 175 (76.1) 0.90 (0.28, 2.94)
pb 0.60 0.89 0.59 0.94
Menopausal hormone use
No 18 (60.0) 190 (74.5) 1.00 111 (72.1) 98 (74.2) 1.00 40 (69.0) 169 (74.1) 1.00 36 (65.4) 172 (74.8) 1.00
Yes 12 (40.0) 63 (24.7) 0.54 (0.23, 1.29) 43 (27.9) 32 (24.2) 0.68 (0.37, 1.23) 17 (29.3) 58 (25.4) 1.59 (0.59, 4.32) 19 (34.6) 56 (24.3) 0.55 (0.27, 1.12)
pb 0.16 0.20 0.68 0.10
Smoking status
Non-smoker 18 (60.0) 179 (70.2) 1.00 98 (63.6) 100 (75.8) 1.00 40 (69.0) 158 (69.3) 1.00 38 (69.1) 159 (69.1) 1.00
Former 7 (23.3) 41 (16.1) 0.70 (0.26, 1.90) 28 (18.2) 20 (15.2) 0.74 (0.37, 1.49) 12 (20.7) 36 (15.8) 0.89 (0.41, 1.98) 10 (18.2) 38 (16.5) 1.05 (0.45, 2.45)
Current 5 (16.7) 35 (13.7) 0.62 (0.20, 1.94) 28 (18.2) 12 (9.1) 0.30 (0.13, 0.68) 6 (10.3) 34 (14.9) 1.59 (0.59, 4.32) 7 (12.7) 33 (14.3) 0.92 (0.35, 2.45)
pb 0.62 0.01 0.60 0.98
Body mass index
<25 10 (33.3) 71 (27.8) 1.00 40 (26.0) 41 (31.1) 1.00 16 (27.6) 65 (28.5) 1.00 13 (23.6) 68 (29.6) 1.00
25–30 8 (26.7) 104 (40.8) 1.75 (0.63, 4.86) 54 (35.1) 58 (43.9) 1.11 (0.60, 2.04) 20 (34.5) 92 (40.3) 0.97 (0.45, 2.09) 18 (32.7) 94 (40.9) 0.92 (0.40, 2.11)
>30 12 (40.0) 77 (30.2) 0.86 (0.32, 2.27) 58 (37.7) 32 (24.2) 0.57 (0.29, 1.11) 22 (37.9) 68 (29.8) 0.68 (0.31, 1.49) 24 (43.6) 65 (28.3) 0.48 (0.21, 1.09)
pb 0.35 0.08 0.53 0.12
Parity
Nulliparous 4 (13.3) 56 (22.0) 1.00 26 (16.9) 34 (25.8) 1.00 11 (19.0) 49 (21.5) 1.00 7 (12.7) 53 (23.0) 1.00
1–2 Live births 22 (73.3) 184 (72.2) 0.51 (0.16, 1.64) 118 (76.6) 89 (67.4) 0.56 (0.30, 1.06) 41 (70.7) 166 (72.8) 0.88 (0.14, 1.79) 43 (78.2) 163 (70.9) 0.43 (0.17, 1.10)
≥3 Live births 4 (13.3) 15 (5.9) 0.18 (0.04, 0.89) 10 (6.5) 9 (6.8) 0.64 (0.21, 1.96) 6 (10.3) 13 (5.7) 0.55 (0.14, 2.24) 5 (9.1) 14 (6.1) 0.26 (0.06, 1.04)
pb 0.11 0.21 0.56 0.12
Oral contraceptive use
Never 28 (93.3) 245 (96.1) 1.00 147 (95.4) 127 (96.2) 1.00 54 (93.1) 220 (96.5) 1.00 53 (96.4) 220 (95.6) 1.00
Ever 2 (6.7) 10 (3.9) 1.18 (0.20, 6.95) 7 (4.5) 5 (3.8) 1.30 (0.34, 4.87) 4 (6.9) 8 (3.5) 0.55 (0.14, 2.24) 2 (3.6) 10 (4.3) 2.79 (0.49, 15.99)
pb 0.85 0.70 0.40 0.25
(Continued)
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of serous epithelial ovarian cancers showed that alterations in
the Rb pathway were sufficient to induce these tumors (34).
Taken together, these findings highlight the overall importance
of this pathway in ovarian carcinogenesis. Although the TCGA
analysis of endometrial cancer did not identify the Rb pathway
as a commonly altered target (32), endometrial cancer case-
series have shown frequent alterations in key players of the Rb
pathway (18–27).
In our study, most of the established risk factors for ovarian
and endometrial cancers were not related to expression of the
CDK inhibitors. Similar to previous ovarian cancer studies (13–15,
35, 36), we observed that positive p21 expression was associated
with well-differentiated, early stage, non-serous ovarian cancer
subtypes, and better survival whereas positive p16 expression was
associated with poorly differentiated tumors (3, 6, 12, 13). Con-
sistent with some previous studies (10–12), and in contrast to
others (4, 5, 8), we did not detect associations between p16 expres-
sion with either stage or histology. Furthermore, no association
between p16 and ovarian cancer survival was observed in our
study; however, previous studies have shown that positive p16
expression is related to both lower (4, 5, 11) and higher mortality
(6, 8). The contradictory findings related to p16 may be due, in
part, to differences in staining protocols, cut-off values for p16
expression, and characteristics of the study populations exam-
ined. Several mechanisms have been described for overexpression
of p16: p16 is a marker of aging and cellular stress, which signals
pRb to halt the cell-cycle and proliferation given negative feed-
back interactions. In this scenario, overexpression of p16 would be
expected among lower grade and early stage tumors. Conversely,
overexpression of p16 could indicate downstream disruption of
pRb signaling – if pRb has been inactivated by other mechanisms,
negative regulation of p16 will not occur, resulting in an accu-
mulation of p16. In this case, overexpression of p16 might be an
indicator of more aggressive tumor characteristics. Furthermore,
recent data suggest that p16 has dual biological roles as tumor
suppressor gene and oncogene, which may in part account for the
inconsistent findings (37).
p27 expression has variably been associated with better tumor
characteristics and improved survival in some ovarian case-series
(17, 38) while others have observed poor tumor characteristics
and unfavorable survival (14, 39, 40). Our results agree with the
latter group of studies, as we observed that p27 expression tended
to be positive in advanced stage and serous ovarian tumors. p27
likely has a complex function in regulating the cell-cycle, which
may explain the inconsistent observations.
In our series of mostly endometrioid endometrial carcino-
mas, we did not observe significant associations between cell-cycle
expression and endometrial tumor characteristics, which agrees
with some (22, 23, 41) but not other studies (19, 21, 26, 27,
42–44). Some have reported that overexpression of p16, p21, or
p27 was significantly associated with poorly differentiated tumors
(26, 43, 44), advanced stage (43), and worse survival (19, 42)
among endometrial cancer patients. Conversely, Salvesen and
colleagues (27) showed that loss of nuclear p16 was associated
with poor tumor characteristics including, advanced stage, serous
or clear cell histology, poorly differentiated tumors, and worse
survival.
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FIGURE 2 | Heat map of cell-cycle marker distributions in histologic subtypes of ovarian and endometrioid endometrial cancer patients. Abbreviations:
HGS, high-grade serous; LGS, low-grade serous; ME, mixed epithelial; MUC, mucinous; EO, endometrioid ovarian cancer; CC, clear cell; EM EC, endometrioid
endometrial cancer.
In addition, we compared expression across the histologic sub-
types using a heat map to visually assess staining patterns. Non-
serous ovarian tumors, including clear cell, endometrioid, and
mixed tumors, displayed similar patterns of expression of p16,
p21, p27, and ki67 while serous ovarian tumors showed opposite
expression patterns of the CDK inhibitors. Endometrioid endome-
trial cancers, which made up of 99% of endometrial cancer cases
included on the TMA, had an expression profile intermediate to
that of non-serous and serous ovarian cancers, with high expres-
sion of p16 and low expression of the other markers. These patterns
likely underscore differences in the pathobiology of these tumors
and potentially have therapeutic implications (45).
Our study had several strengths including a relatively large
number of cases for each tumor site with tumor tissue, availability
of epidemiologic risk factor data, and high quality pathology data,
as well as uniform evaluation of the immunostains. Some limi-
tations of our analysis, which can be addressed in future studies,
include limited numbers of cases within histologic subgroups and
limited diversity of endometrial cancer subtypes. Furthermore,
studies that examine ratios between stimulatory and inhibitory
proteins of the cell-cycle e.g., cyclins and CDK inhibitors, may
provide additional information beyond expression of individual
proteins (46).
In conclusion, this is the first study to evaluate associations
between cell-cycle biomarkers, risk factors, and tumor character-
istics for two gynecologic malignancies. Our study suggests that
the CDK inhibitors p16, p21, and p27 are minimally associated
with epidemiologic risk factors for development of these tumors.
Significant associations between CDK inhibitors, tumor charac-
teristics, and survival were observed and support the growing
body of literature related to the CDK/RB pathway for prognosis in
gynecological cancers.
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